HC Wainwright Cuts Earnings Estimates for Palisade Bio

Key Points

• HC Wainwright lowered its FY2026 EPS estimate for Palisade Bio to a loss of $0.24 per share from $0.20, while maintaining a Buy rating and a $5 price target.
• Palisade Bio reported a quarterly loss of $0.07 per share, missing the consensus estimate of a $0.06 loss by $0.01.
• Analyst sentiment overall remains positive: MarketBeat reports a consensus Buy rating and $9 average price target, with two Strong Buy, seven Buy, and one Sell rating.

Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Equities researchers at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for shares of Palisade Bio in a report released on Wednesday, November 11th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($0.24) for the year, down from their prior forecast of ($0.20). HC Wainwright has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for Palisade Bio's current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Palisade Bio's Q4 2026 earnings at ($0.07) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.33) EPS.

Palisade Bio (NASDAQ:PALI - Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.01).

A number of other equities research analysts also recently commented on PALI. Oppenheimer reaffirmed an "outperform" rating on shares of Palisade Bio in a report on Wednesday, October 21st. Weiss Ratings reiterated a "sell (e+)" rating on shares of Palisade Bio in a report on Monday, October 12th. Raymond James Financial began coverage on shares of Palisade Bio in a report on Thursday, October 8th. They issued an "outperform" rating and a $6.00 price target on the stock. Finally, Wall Street Zen lowered shares of Palisade Bio from a "hold" rating to a "sell" rating in a research report on Saturday, October 17th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Palisade Bio presently has a consensus rating of "Buy" and a consensus target price of $9.00.

Palisade Bio Stock Down 2.6%

Shares of NASDAQ:PALI opened at $1.14 on Friday. Palisade Bio has a 52-week low of $1.08 and a 52-week high of $2.85. The stock has a market cap of $204.38 million, a price-to-earnings ratio of -2.38 and a beta of 1.61. The business has a 50-day moving average price of $1.50 and a 200-day moving average price of $1.82.

Institutional Investors Weigh In On Palisade Bio

Hedge funds have recently added to or reduced their stakes in the business. Jupiter Topco LLC purchased a new position in shares of Palisade Bio during the 2nd quarter valued at about $22,394,000. BlackRock Inc. acquired a new position in shares of Palisade Bio in the 2nd quarter valued at about $21,813,000. Janus Henderson Group PLC lifted its holdings in shares of Palisade Bio by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company's stock valued at $18,760,000 after buying an additional 149,118 shares during the period. Octagon Capital Advisors LP boosted its stake in shares of Palisade Bio by 7.4% in the first quarter. Octagon Capital Advisors LP now owns 10,276,317 shares of the company's stock worth $17,984,000 after buying an additional 708,419 shares during the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of Palisade Bio by 27.5% in the second quarter. Wellington Management Group LLP now owns 3,703,936 shares of the company's stock worth $7,741,000 after buying an additional 799,025 shares during the last quarter. 11.79% of the stock is owned by hedge funds and other institutional investors.

Palisade Bio Company Profile

Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions. Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn's disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.